Neisseria gonorrhoeae therapeutic based on CMP-nonulosonate sugars
US10865222B2 · kind B2 · utility
0Cited by
0References
18Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Sep 1, 2017 |
| Grant date | Dec 15, 2020 |
| Priority date | — |
| Expiry date | Sep 1, 2037 |
Classification
- Technology area (CPC Y)Emerging Cross-Sectional Technologies
- CPC primaryY02A50/30
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
N. gonorrhoeae has become resistant to almost every conventional antibiotic. Described herein is the use of CMP-nonulosonate analogues to counter gonococcal complement evasion. The nonulosonate sugar is incorporated into the lipooligosaccharide of the N. gonorrhoeae which in turn reduces the serum resistance of the bacteria. This provides a novel therapeutic strategy against the global threat of multi-drug resistant gonorrhea.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.